HK1201562A1 - 類新穎的以蛋白質為基礎的治療用分子 - Google Patents

類新穎的以蛋白質為基礎的治療用分子

Info

Publication number
HK1201562A1
HK1201562A1 HK15102164.9A HK15102164A HK1201562A1 HK 1201562 A1 HK1201562 A1 HK 1201562A1 HK 15102164 A HK15102164 A HK 15102164A HK 1201562 A1 HK1201562 A1 HK 1201562A1
Authority
HK
Hong Kong
Prior art keywords
therapeutic protein
protein based
novel class
based molecules
molecules
Prior art date
Application number
HK15102164.9A
Other languages
English (en)
Inventor
房芳
邁克爾‧馬拉科夫
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Publication of HK1201562A1 publication Critical patent/HK1201562A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
HK15102164.9A 2004-09-10 2015-03-03 類新穎的以蛋白質為基礎的治療用分子 HK1201562A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/939,262 US7807174B2 (en) 2002-11-22 2004-09-10 Class of therapeutic protein based molecules

Publications (1)

Publication Number Publication Date
HK1201562A1 true HK1201562A1 (zh) 2015-09-04

Family

ID=36060467

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15102164.9A HK1201562A1 (zh) 2004-09-10 2015-03-03 類新穎的以蛋白質為基礎的治療用分子
HK16112471.5A HK1224329A1 (zh) 2004-09-10 2016-10-28 種新型的以蛋白為基礎的治療用分子

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16112471.5A HK1224329A1 (zh) 2004-09-10 2016-10-28 種新型的以蛋白為基礎的治療用分子

Country Status (17)

Country Link
US (2) US7807174B2 (zh)
EP (4) EP3241898B1 (zh)
JP (2) JP4764881B2 (zh)
KR (1) KR20070064619A (zh)
CN (2) CN104017787B (zh)
AU (1) AU2005285461B2 (zh)
BR (1) BRPI0515646B8 (zh)
CA (2) CA2823429C (zh)
DK (3) DK3241898T3 (zh)
ES (3) ES2721172T3 (zh)
HK (2) HK1201562A1 (zh)
IL (3) IL181779A (zh)
PT (3) PT3241898T (zh)
RU (1) RU2468080C2 (zh)
TR (1) TR201905393T4 (zh)
WO (1) WO2006031291A2 (zh)
ZA (1) ZA200702915B (zh)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
US8512710B2 (en) * 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
EP1567185B1 (en) * 2002-11-22 2020-02-19 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
CN102917536B (zh) * 2004-11-10 2016-06-22 日立化成株式会社 附有粘着辅助剂的金属箔及使用其的印刷配线板
US20090220941A1 (en) * 2005-10-25 2009-09-03 Mnd Diagnostic Ltd Compositions for- detecting of influenza viruses and kits and methods using same
AU2013237761B8 (en) * 2006-01-24 2015-06-04 Ansun Biopharma, Inc. Technology for preparation of macromolecular microspheres
KR102180849B1 (ko) * 2006-01-24 2020-11-20 안선 바이오파르마, 아이엔씨. 고분자 미소 구체들의 조제를 위한 기술
AU2015215955B2 (en) * 2006-01-24 2016-12-01 Ansun Biopharma, Inc. Technology for preparation of macromolecular microspheres
US8273381B1 (en) * 2006-04-14 2012-09-25 Auburn University Compositions for and methods of controlling olfactory responses to odorants
WO2008076938A1 (en) * 2006-12-14 2008-06-26 University Of Iowa Research Foundation Method of making cyclic polypeptides with inteins
CA2676686C (en) * 2007-02-20 2015-12-15 Dsm Ip Assets B.V. Novel sialidase
ES2550755T3 (es) 2007-08-03 2015-11-12 Romark Laboratories, L.C. Compuestos de tiazolida sustituidos con alquilsulfonilo
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
KR20170141830A (ko) * 2009-06-26 2017-12-26 로마크 레버러토리즈, 엘.씨. 인플루엔자를 치료하기 위한 화합물 및 방법
AR076311A1 (es) * 2009-07-31 2011-06-01 Danisco Us Inc Proteasas con regiones pre- pro modificadas
EP2496251A4 (en) * 2009-11-06 2013-10-30 Nexbio Inc METHODS, COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF THE RESPIRATORY TRACT
CN104203267A (zh) * 2012-02-17 2014-12-10 安迅生物制药公司 用于治疗流感和副流感患者的方法、化合物和组合物
US20140099380A1 (en) 2012-06-28 2014-04-10 Ansun Biopharma, Inc. Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture
EP2877204A2 (en) * 2012-06-28 2015-06-03 Ansun Biopharma, Inc. Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture
BR112015015182B1 (pt) 2012-12-24 2023-12-26 Coagulant Therapeutics Corporation Variante polipeptídica isolada do fator vii, seu método de preparação e seu uso, e composições farmacêuticas e seus usos
AU2014239573B2 (en) * 2013-03-15 2019-11-21 Ansun Biopharma, Inc. Novel method of protein purification
WO2014197485A1 (en) * 2013-06-03 2014-12-11 Ansun Biopharma, Inc. Anti-viral therapeutic for infection of the eye
WO2014201034A2 (en) * 2013-06-10 2014-12-18 Ansun Biopharma, Inc. Treatment for polyomavirus infection
US20160120961A1 (en) * 2013-06-10 2016-05-05 Ansun Biopharma, Inc. Treatment of merkel cell polyomavirus infection
WO2015184356A1 (en) 2014-05-30 2015-12-03 Ansun Biopharma, Inc. Treatment of middle east respiratory syndrome coronavirus
WO2016044656A1 (en) 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
WO2016115616A1 (en) * 2015-01-21 2016-07-28 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Inhibition of cellular proteases as treatment for influenza
CA3030261A1 (en) 2015-07-21 2017-01-26 Thomas Jefferson University Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
DK3478314T3 (da) 2016-07-01 2023-06-19 Univ Leland Stanford Junior Konjugater til målrettet celleoverflade-editering
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR102609790B1 (ko) 2017-05-26 2023-12-04 게노비스 에이비 O-당단백질에 대한 프로테아제 및 결합 폴리펩티드
AU2018328223A1 (en) 2017-09-05 2020-03-12 GLAdiator Biosciences, Inc. Delivery of payloads to stem cells
CA3087529A1 (en) 2018-01-03 2019-07-11 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
GB201800274D0 (en) * 2018-01-08 2018-02-21 Enzymatica Ab Novel treatments
GB201803197D0 (en) 2018-02-27 2018-04-11 Pneumagen Ltd Viral treatment
JP2021531042A (ja) * 2018-07-20 2021-11-18 アンサン バイオファーマ, インク.Ansun Biopharma, Inc. 癌細胞、免疫細胞及び腫瘍微小環境へのシアリダーゼの送達
CN109991649B (zh) * 2019-03-26 2021-04-06 华中科技大学 一种制备无机闪烁体膜的方法
JP7343890B2 (ja) * 2019-04-26 2023-09-13 国立大学法人東海国立大学機構 シアリダーゼ活性を有する酵素剤及びその利用
CN110038122A (zh) * 2019-05-23 2019-07-23 武汉真福医药股份有限公司 枯草杆菌纤溶酶在治疗支气管炎药物中的应用
JPWO2021002355A1 (zh) 2019-07-03 2021-01-07
CN111450236B (zh) * 2020-02-25 2023-04-07 西北大学 一种用于阻断冠状病毒感染的制剂
WO2021217053A1 (en) * 2020-04-24 2021-10-28 Rezolute, Inc. Plasma kallikrein inhibitors for the treatment of ards and related conditions
US20230218794A1 (en) * 2020-06-10 2023-07-13 The Penn State Research Foundation Process and system to lessen human coronavirus transmission and spread
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen
JP2024524875A (ja) * 2021-06-09 2024-07-09 マイクロビアル マシーンズ， インコーポレイテッド 疾患細胞を検出するための操作された微生物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3439089A (en) 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
CA1340173C (en) * 1987-03-10 1998-12-08 Chudi Guan Production and purification of a protein fused to a binding protein
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
US5376633A (en) 1992-09-30 1994-12-27 Lezdey; John Method for deactivating viruses in blood component containers
US5985859A (en) 1994-04-14 1999-11-16 The University Of Alabama Methods of inhibiting bacterial sialidase
EP0716702B1 (en) * 1994-06-14 2002-08-28 Genencor International, Inc. Thermostable xylanases
HU228450B1 (en) * 1995-02-27 2013-03-28 Gilead Sciences Inc Novel selective inhibitors of viral or bacterial neuraminidases
GB9513683D0 (en) * 1995-07-05 1995-09-06 Ciba Geigy Ag Products
AU5546898A (en) 1997-01-14 1998-08-07 Hopital Sainte-Justine Human lysosomal sialidase and therapeutic uses thereof
US6251392B1 (en) 1997-10-20 2001-06-26 Epicyte Pharmaceuticals, Inc. Epithelial cell targeting agent
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20020025320A1 (en) 1999-08-20 2002-02-28 Prosper Boyaka Sialidases as mucosal adjuvants
CN1405562A (zh) * 2002-10-24 2003-03-26 肖洪武 一种唾液酸酶测定试剂
EP1567185B1 (en) 2002-11-22 2020-02-19 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
DE10258400A1 (de) * 2002-12-13 2004-06-24 N.V. Nutricia Trans-Sialidasen aus Trypanosoma congolense
KR102180849B1 (ko) 2006-01-24 2020-11-20 안선 바이오파르마, 아이엔씨. 고분자 미소 구체들의 조제를 위한 기술

Also Published As

Publication number Publication date
EP3241898B1 (en) 2019-01-23
US7807174B2 (en) 2010-10-05
BRPI0515646A8 (pt) 2017-04-04
EP3241898A1 (en) 2017-11-08
JP4764881B2 (ja) 2011-09-07
RU2468080C2 (ru) 2012-11-27
BRPI0515646B8 (pt) 2021-05-25
DK1786902T3 (en) 2015-10-19
EP1786902B1 (en) 2015-09-09
ES2721172T3 (es) 2019-07-29
IL181779A (en) 2015-10-29
KR20070064619A (ko) 2007-06-21
EP1786902A2 (en) 2007-05-23
US7645448B2 (en) 2010-01-12
US20050112751A1 (en) 2005-05-26
JP5307082B2 (ja) 2013-10-02
EP1786902A4 (en) 2009-12-09
JP2008512117A (ja) 2008-04-24
BRPI0515646A (pt) 2008-07-15
RU2007112502A (ru) 2008-10-20
CN104017787B (zh) 2017-03-29
PT3241898T (pt) 2019-05-20
ZA200702915B (en) 2008-11-26
HK1224329A1 (zh) 2017-08-18
AU2005285461A1 (en) 2006-03-23
DK3018204T3 (en) 2017-07-31
WO2006031291A3 (en) 2009-04-16
CN101426906A (zh) 2009-05-06
CA2578050C (en) 2015-04-21
IL241227A0 (en) 2015-11-30
BRPI0515646B1 (pt) 2020-10-13
CA2578050A1 (en) 2006-03-23
IL207957A0 (en) 2010-12-30
CA2823429A1 (en) 2006-03-23
PT1786902E (pt) 2015-12-22
IL207957A (en) 2016-10-31
CN101426906B (zh) 2013-06-26
DK3241898T3 (en) 2019-04-29
EP3018204B1 (en) 2017-04-12
CA2823429C (en) 2019-06-04
IL181779A0 (en) 2007-07-04
TR201905393T4 (tr) 2019-05-21
IL241227B (en) 2020-05-31
EP3530734A1 (en) 2019-08-28
US20090142327A1 (en) 2009-06-04
WO2006031291A2 (en) 2006-03-23
CN104017787A (zh) 2014-09-03
ES2554787T3 (es) 2015-12-23
JP2010279366A (ja) 2010-12-16
AU2005285461B2 (en) 2011-03-03
EP3018204A1 (en) 2016-05-11
PT3018204T (pt) 2017-07-13
ES2626845T3 (es) 2017-07-26

Similar Documents

Publication Publication Date Title
HK1224329A1 (zh) 種新型的以蛋白為基礎的治療用分子
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
IS8397A (is) Meðferðarfræðilegar bindisameindir
ATE465180T1 (de) Therapeutische anti-igfr1-antikörper- kombinationen
DE502005007353D1 (de) Zervikale zwischenwirbelprothese
EP1789027A4 (en) Therapeutic Use of Anti- TF Antigen Antibodies
IL177155A0 (en) Therapeutic combinations
GB0426160D0 (en) Production of proteins
DK1597171T3 (da) Terapeutisk mikroskum
IL183106A0 (en) Production of proteins
HK1155670A1 (en) Therapeutic use of anti-cs1 antibodies
GB0526120D0 (en) Therapeutic peptides
EP1942911A4 (en) THERAPEUTIC MOLECULES AND USES THEREOF
IL178517A0 (en) Therapeutic peptides
GB0412186D0 (en) Production of recombinant protein
IL185691A0 (en) Novel compounds derived from 5-thioxylose and therapeutic use thereof
GB0412793D0 (en) Therapeutic product
ZA200609395B (en) Therapeutic peptides
IL165427A0 (en) Targeted therapeutic proteins
EP1824453A4 (en) TRANSFER OF MOLECULES
AU2005905434A0 (en) Stabilised therapeutic molecules
GB0419594D0 (en) Therapeutic peptides
AU2003905300A0 (en) Therapeutic molecules
GB0407710D0 (en) Treatment of diseases
GB0409122D0 (en) Protein variants